Hematology

December 02, 2022

The FDA has approved olutasidenib capsules to treat patients with relapsed or refractory acute myeloid leukemia with identified an IDH1-mutation. The label comes with a boxed warning for differentiation syndrome, and a warning for hepatotoxicity.

December 02, 2022

Nurse investigators created an enteral nutrition standardized pathway for pediatric patients about undergoing hematopoietic stem cell transplantation.

November 28, 2022

In light of findings from the phase 3 DREAMM-3 trial, manufacturers have elected to withdraw belantamab mafodotin-blmf from the United States market.

November 27, 2022

Combining ponatinib with reduced-intensity chemotherapy elicited a high rate of minimal residual disease (MRD)-negative complete remissions and no new safety signals in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

November 24, 2022

Patients who receive high cumulative doses of triple intrathecal therapy may be at an increased risk of neurocognitive problems.

November 22, 2022

Ibrutinib demonstrated encouraging responses for patients with relapsed/refractory mantle cell lymphoma in a real-world setting.

November 21, 2022

Coadministration CD19- and CD22-directed CAR T-cell therapy produced relatively durable remissions in children with high-risk hematologic or isolated extramedullary relapse of B-acute lymphoblastic leukemia.

November 16, 2022

In this episode of "The Vitals," Ellen Miller, MSN, FNP-BC, talks about meeting a patient who realized she wanted to get pregnant after undergoing chemoradiation as a teenager.

November 16, 2022

The FDA has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients with classical Hodgkin lymphoma.

November 10, 2022

Daniel J. Verina, DNP, RN, MSN, ACNP-BC, underscores how nurses can assess neurological toxicities in both the inpatient and outpatient setting.